<?xml version="1.0" encoding="UTF-8"?>
<p id="p0145">FcRn is a critical regulator of IgG half-life. This receptor works by preventing degradation and clearance of IgG, by a pinocytotic mechanism that allow antibody circulation within the cell for its posterior excretion [
 <xref rid="bb0325" ref-type="bibr">65</xref>,
 <xref rid="bb0375" ref-type="bibr">75</xref>]. The FcRn inhibitor rozanolixizumab showed reduction of IgG concentrations in a phase 1 study [
 <xref rid="bb0380" ref-type="bibr">76</xref>], and it proved to be critical in IVIg catabolism in common variable immunodeficiency patients [
 <xref rid="bb0385" ref-type="bibr">77</xref>]. It has been demonstrated that saturation of this receptor by IVIg may account as the most likely mechanism to clear autoantibodies in autoimmune conditions by shortening their lifetime [
 <xref rid="bb0390" ref-type="bibr">[78]</xref>, 
 <xref rid="bb0395" ref-type="bibr">[79]</xref>, 
 <xref rid="bb0400" ref-type="bibr">[80]</xref>]. Whether antibodies play a critical role in COVID-19 pathogenesis stills remain to be elucidated, however, the saturation of FcRn may provide an additional immunomodulatory pathway in patients receiving CP.
</p>
